Maintaining glucose integrity ex-vivo: Impact of preanalytical specimen handling.

Abstract

Adopting the WHO protocol for glucose analysis is arguably impractical in the routine clinical setting. Deviations may develop due to a lack of understanding regarding the impact of glycolysis on the accuracy of results. We sought to assess the stability of glucose in two different blood collection tubes (BCT), BD Vacutainer® FX 'Fl-Ox' and Greiner Vacuette® FC-Mix 'FC-Mix' stored at room temperature (RT:18-22°C) and 4°C over 8.5days. Each participant provided venous whole blood collected into 51 BCTs; 'Fl-Ox' (n = 26) and 'FC-Mix' (n = 25). One Fl-Ox sample from each participant was handled according to the WHO recommended method. The remaining BCTs were stored at 4°C/RT prior to analyses at designated study timepoints. Glucose was measured using the hexokinase assay on the Cobas® 8000 platform. Participants (n = 8, Male = 2) were aged 24-56years. Plasma glucose measured in FI-Ox BCTs according to the WHO sample-handling method had a median concentration of 5.73mmol/L (Range: 5.39-10.37mmol/L). Glucose decreased by greater than minimal difference (>0.26mmol/L) in blood collected into Fl-Ox and stored @4°C/RT within 24h of phlebotomy. FC-Mix BCT maintained glucose <0.26mmol/L @4°C over a period of 8.5days and up to 4days @RT when compared to the WHO recommended method. Glucose in FC-Mix BCT stored @4°C demonstrated the best agreement with results determined using the WHO specifications. When FC-Mix tubes were stored @RT, glucose was stable for 4days. These findings suggest that the FC-Mix BCT effectively inhibits glycolysis and should be introduced into routine clinical practice.